Maxime Frelaut
@mfrelaut.bsky.social
Medical Oncologist at Gustave Roussy, France. Head of the geriatric oncology unit. Interested in geriatric, thoracic and GU oncology.
📢 Webinaire HOT d'OG @SOFOG @DIALOG
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
April 7, 2025 at 11:19 AM
📢 Webinaire HOT d'OG @SOFOG @DIALOG
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
February 15, 2025 at 11:23 PM
Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
At #MAO2025, Dr. Camille Chakiba presented the PRIORITY study on cancer patients’ care goals:
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
January 31, 2025 at 2:02 PM
At #MAO2025, Dr. Camille Chakiba presented the PRIORITY study on cancer patients’ care goals:
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
📢 #MAO2025 | Chemo + IO in metastatic NSCLC for ≥65:
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
January 31, 2025 at 1:44 PM
📢 #MAO2025 | Chemo + IO in metastatic NSCLC for ≥65:
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
🔬 ADC & elderly breast cancer patients 👵🎗️
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
January 30, 2025 at 4:20 PM
🔬 ADC & elderly breast cancer patients 👵🎗️
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
📢 Capucine Baldini at MAO 2025:
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy
January 30, 2025 at 9:44 AM
📢 Capucine Baldini at MAO 2025:
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy